Publication Date: October 2026 (Volume 28, Number 10)
CME Credits: 4 AMA PRA Category 1 Credits™, 4 ACEP Category I credits, 4 AAFP Prescribed credits, and 4 AOA Category 2-B CME credits. CME expires 10/01/2029.
Specialty CME Credits: Included as part of the 4 credits, this CME activity is eligible for 4 Pharmacology CME credits and 0.25 Risk Management CME credits, subject to your state and institutional approval.
Authors
The expanding use of antiplatelet agents, anticoagulants, and fibrinolytics has made bleeding emergencies more frequent and more complex. A structured, evidence-based approach enables emergency clinicians to identify life-threatening and critical-site bleeding, initiate resuscitation, establish which antithrombotic agent the patient received and when, and weigh the benefit of restoring hemostasis against the risk for thrombosis. This review synthesizes current guidelines and evidence on the evaluation and management of bleeding in patients receiving antithrombotic therapy, identifying areas of consensus and ongoing uncertainty. Coagulation assays, agent-specific reversal and hemostatic strategies, periprocedural management, and bleeding in pregnancy are addressed.
A 65-year-old woman presents to a critical access hospital ED after being a passenger in a high-speed motor vehicle crash…
A 40-year-old man with a history of cirrhosis presents with hematemesis…
A 60-year-old woman presents to a community ED after being found obtunded in bed. She was last seen normal approximately 10 hours ago…
EB Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.